共 51 条
[1]
Robison G.A., Butcher R.W., Sutherland E.W., Cyclic AMP, (1971)
[2]
Burns F., Zhao A.Z., Beavo J.A., Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiologic implications, Adv Pharmacol Academic Press, 36, pp. 29-48, (1996)
[3]
Corbin J.D., Francis S.H., Cyclic GMP phosphodiesterase-5: target for sildenafil, J Biol Chem, 274, pp. 13729-13732, (1999)
[4]
Francis S.H., Turko I.V., Corbin J.D., Cyclic nucleotide phosphodiesterases: relating structure and function, Prog Nucleic Acid Res Mol Biol, 65, pp. 1-52, (2001)
[5]
Soderling S.H., Beavo J.A., Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Curr Opin Cell Biol, 12, pp. 174-179, (2000)
[6]
Jeremy J.Y., Ballard S.A., Naylor A.M., Et al., Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro, Br J Urol, 79, pp. 958-963, (1997)
[7]
Ballard S.A., Gingell C.J., Tang K., Et al., Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes, J Urol, 159, pp. 2164-2171, (1998)
[8]
Corbin J.D., Francis S.H., Pharmacology of phosphodiesterase-5 inhibitors, Int J Clin Pract, 56, pp. 453-459, (2002)
[9]
Rotella D.P., Phosphodiesterase 5 inhibitors: current status and potential applications, Nat Rev Drug Discov, 1, pp. 674-682, (2002)
[10]
Hellstrom W.J., Gittelman M., Karlin G., Et al., Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, pp. 763-771, (2002)